| Literature DB >> 35855822 |
Chao Ke1, Shengtao Shan1, Chuang Fang1, Yewan Xia1, Wei Zhang1.
Abstract
Background: This review aims to systematically summarize and analyze recent high-quality animal research results about the use of acupuncture in Alzheimer's disease (AD) patients. This information will be useful in providing a reference for future experimental research and an experimental basis for the clinical use of acupuncture in the treatment of AD.Entities:
Year: 2022 PMID: 35855822 PMCID: PMC9288276 DOI: 10.1155/2022/8243704
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Flow diagram of the study selection.
Figure 2Overview of included studies by year.
Overview of included studies by journal.
| Journals | Studies, |
|---|---|
| Evidence-based complementary and alternative medicine | 9 |
| Neural regeneration research | 8 |
| Acupuncture in medicine | 7 |
| Neural plasticity | 6 |
| Frontiers in neuroscience | 4 |
| Frontiers in aging Neuroscience, Journal of traditional Chinese Medicine, Medical science monitor | 3 |
| BMC complementary and alternative Medicine, Behavioral Neurology, Molecular Neurobiology, Neuroreport, Journal of alternative and complementary medicine | 2 |
| Free radical biology & Medicine, Frontiers in Pharmacology, Genes & diseases, Integrative medicine Research, Iranian journal of basic medical Sciences, Journal of Alzheimer's Disease, Journal of biomedical and translational Research, Journal of traditional Chinese medical Sciences, Journal of integrative neuroscience, Anatomical Record, Autophagy, Metabolic brain Disease, Molecular medicine Reports, Biological Research, Brain Research, Cellular and molecular biology, Neuropsychiatric disease and Treatment, Current alzheimer Research, Neuroscience Letters, PloS One, World journal of stem Cells, Journal of neuroinflammation | 1 |
a∗b, a means the number of articles in a journal, b means the number of journals.
Figure 3Overview and map of included studies by country of publication.
Animal selections.
| Strain | Number of studies ( | Sex ( | Age ( |
|---|---|---|---|
| SAMP8 mice | 31 | Male (27), female (1), unknown (3) | 8 months (9), 7 months (8), 7.5 months (6), 4 months (1), 6 months (1), 10 months (1), 2/6/8/12 different months (1),7/9/11 different months (1), unknown (3) |
| APP/PS1 double transgenic mice | 17 | Male (12), female (1), unknown (4) | 7 months (6), 6 months (4), 3 months (1), 4 months (1), 5 months (1), 9 months (1), 12 months (1), 4/12 different months (1), unknown (1) |
| SD rat | 14 | Male (8), half of each sex(2), female (1), unknown (3) | 3 months (3), 2 months (1), 6 months (1), 22–24 months (1), unknown (8) |
| Wistar rat | 6 | Male (3), half of each sex(2), unknown (1) | 2 months (2), 4–5 months (2), 12 months (1), unknown (1) |
| 5xFAD mice | 4 | Male (1), female (3) | 6.5 months (3), 5.5 months (1) |
| OLETF rat | 1 | Male (1) | 3 months (1) |
| PScDKO mice | 1 | Unknown (1) | 4 months (1) |
| ApoE−/−mice | 1 | Male (1) | 2 months (1) |
Animal models.
| Type ( | Modeling method ( | Model validation ( |
|---|---|---|
| Transgenic model (54) | Directly select SAMP8 mice as model (31) | Gene identification (7), open field test (1), unknown (46) |
| Directly select APP/PS1 double transgenic mice as model (17) | ||
| Directly select 5XFAD mice expressing gene mutations (4) | ||
| PScDKO mice by crossing the forebrain-specific PS1 heterozygous knockout mice with conventional PS2 heterozygous knockout mice (1) | ||
| Directly select ApoE−/−mice with high-fat diet as model (1) | ||
| Surgical model (21) | Intraperitoneal injections of D-gal for 6 weeks + Bilateral hippocampal injections of A | Y maze (3), morris water maze test (2), unknown (16) |
| Bilateral lateral ventricles injections of A | ||
| Bilateral hippocampal injections of A | ||
| Intraperitoneal injections of D-gal for 8 weeks (3) | ||
| Bilateral hippocampal injections of A | ||
| Intraperitoneal injections of D-gal for 6 weeks + Right NBM injections of IBA (2) | ||
| Left hippocampus injections of A | ||
| Bilateral hippocampal injections of A | ||
| Intraperitoneal injections of D-gal for 6 weeks + Bilateral basal nuclei injections of ibotenic acid (1) | ||
| Intraperitoneal injections of D-gal for 90 days + Intragastric administrations of AlCl3 for 90 days (1) |
Treatment methods.
| Treatment method ( | Retention time ( | Number of treatment sessions ( | Treatment duration ( |
|---|---|---|---|
| EA (50), MA (19), Moxibustion (5), EA + Moxibustion (1) | 20 min (29), 15 min (17), 30 min (13), 10 min (5), unknown (11) | 14 (15), 24 (14), 15 (12), 20 (6), 48 (5), 28 (4), 18 (3), 6 (3), 30 (2), 40 (2), 56 (2), 12 (1), 21 (1), 26 (1), 72 (1), unknown (3) | 15 days, once a day, day 8 rest (12), 15 days, once a day (9), 4 weeks, once a day, 6 days per week (8), 4 weeks, once a day, 5 days per week (6), 30 days, once a day, 8 days of every 10 days (5), 4 weeks, once a day (4), 8 weeks, once a day, 6 days per week (4), 2 weeks, 3 days per week (3), 3 weeks, once a day, 6 days per week (3), 4 weeks, every other day (3), 8 weeks, once a day (2), 30 days, every other day (2),8 weeks, once a day, 5 days per week (2), 12 weeks, once a day, 6 days per week (1), 6 weeks, once a day, 5 days per week (1), 3 weeks, once a day, 5 days per week (1), 16 weeks, once a day, 3 days per week (1), 2 weeks, once a day, 6 days per week (1), 6 weeks, every other day (1), 3 weeks, once a day (1), 26 days, once a day (1), 30 days, once a day (1), unknown (3) |
Parameter settings for EA administration.
| Brand ( | Model ( | Waveform ( | Frequency ( | Electric current ( |
|---|---|---|---|---|
| Hans electronic acupuncture apparatus (22) | HANS-LH202 (14), HANS-100A (5), HANS-200 (3) | Continuous (15) sparse (9), disperse (4), sparse and dense (3), dense (1), unknown (21) | 1/15 Hz (1), 80–100 Hz (1), unknown (4) | 1 mA (25), 0.6 mA (5), 0.1 mA (5), 1.5 mA (2), ≤2 mA (2), 2 mA (2), 20 mA (1), 1–2 mA (1), 1–3 mA (1), 0.3 mA (1), unknown (8) |
| G6805 acupuncture apparatus (11) | G6805- II (5), G6805-2A (1), unknown (5) | |||
| Other (20) | Hwato (5), ZJ-12H music EA device (2), Master-8 stimulator (2), Korean brand (2), unknown (9) |
Acupoints and acupoint prescriptions of included studies.
| Acupoint prescription ( | Acupoint ( | Meridian ( |
|---|---|---|
| Single point (20), | GV20 (46), EX-HN3 (21), | GV (91) |
| GV20 + EX-HN3 + GV26 (12), | GV26 (13), GV24 (6), GV14 (5) | CV (32) |
| GV20 + BL23 (10), | CV17 (9), CV12 (9), CV4 (8), | BL (19) |
| GV20 + EX-HN3 (6), | CV6 (5), CV8 (1) | SP (12) |
| CV17 + CV12 + CV6 + ST36 + SP10 (5), | BL23 (18), BL17 (1) | KI (6) |
| RN17 + CV12 + CV4 + ST36 + SP10 (4), | SP10 (10), SP6 (2) | ST (13) |
| GV24 + GB13 (4), BL23 + GV14 (4), | KI3 (4), KI1 (2) | GB (4) |
| EX-HN3 + LI20 (3), GV20 + KI1 (2), | ST36 (13) | LI (3) |
| GV20 + GV24 (2), GV20 + GV26 (1), | GB13 (4) | PC (1) |
| GV20 + ST36 (1), GV20 + BL23 + KI3 (1), | LI20 (3) | HT (1) |
| GV20 + GV14 + BL23 (1), | PC6 (1) | |
| GV20 + BL23 + SP10 + BL17 (1), | HT7 (1) | |
| GV20 + BL23 + PC6 + ST36 + SP6 (1) |
Figure 4The locations of 21 selected acupoints for AD treatment in included studies.
Analysis of the association rule of the combinations of common acupoints in treatment of AD with acupuncture.
| Number | Acupoints | Cases | Support (%) | Confidence (%) | Rule support (%) | Lift |
|---|---|---|---|---|---|---|
| 1 | GV20 ⟶ EX-HN3 | 21 | 26.92 | 85.71 | 23.08 | 1.45 |
| 2 | GV20 ⟶ BL23 | 18 | 23.08 | 77.78 | 17.95 | 1.32 |
| 3 | GV20 ⟶ GV26 | 13 | 16.67 | 100.00 | 16.67 | 1.70 |
| 4 | EX-HN3 ⟶ GV26 | 13 | 16.67 | 92.31 | 15.38 | 3.43 |
| 5 | EX-HN3 ⟶ GV26 and GV20 | 13 | 16.67 | 92.31 | 15.38 | 3.43 |
| 6 | GV20 ⟶ GV26 and EX-HN3 | 12 | 15.38 | 100.00 | 15.38 | 1.70 |
| 7 | CV17 ⟶ SP10 | 10 | 12.82 | 90.00 | 11.54 | 7.80 |
| 8 | CV12 ⟶ SP10 | 10 | 12.82 | 90.00 | 11.54 | 7.80 |
| 9 | ST36 ⟶ SP10 | 10 | 12.82 | 90.00 | 11.54 | 5.40 |
By setting the minimum support >12% and the minimum confidence >70%, a total of nine sets of associated records were obtained.
Figure 5Association network graph of acupoint combinations in the treatment of AD with acupuncture (apriori-based algorithm). The width of the line indicates the support degree.
Figure 6Core acupoint association network of acupoint combinations in the treatment of AD with acupuncture (partition-based algorithm). The size of the circle represents the frequency, and the width of the line indicates the support degree. Node value: 19. Edge value: 35.
Experimental groups.
| Treatment method ( | Positive control groups ( | Sham acupuncture groups or nonacupoint groups ( | Sham-operated control groups ( | Miscellaneous groups ( |
|---|---|---|---|---|
| EA (50) | donepezil hydrochloride (7), memantine (1), selegiline (1) | Sham-EA (5), nonacupoint (6) | Equal volume of saline (7), equal volume of water/acetonitrile mixture (1) | Olfactory stimulation (2), Autophagy inhibitor (1), JNK pathway blocker (1), olfactory nerve cut group (1), DNMT inhibitor (1), NLPR3 inflammasome selective inhibitor (1), autophagy-lysosome pathway group (1) |
| MA (19) | donepezil hydrochloride (4) | Nonacupoint (13) | — | The neural stem cell (NSC) group (3), PDK1/nPKC/Rac1 inhibitor group (1) |
| Moxibustion (5) | — | sham moxibustion (2) | — | — |
| Moxibustion + EA(1) | — | — | Equal volume of saline (1) | — |
Behavioral tests.
| Tests ( | Evaluation indicators ( |
|---|---|
| Morris water maze test (61) | Hidden platform trial: Escape latency (59), swimming distance (8), swimming speed (6). |
| Probe trial test: platform crossing times (37), time spent in the target quadrant (26), ratio of swimming time in the target quadrant and total swimming time (13), ratio of swimming distance in the target quadrant and total swimming distance (5), swimming speed (5). Swimming distance in the target quadrant (4), latency to first target-site crossover (3), ratio of swimming time in every quadrant and total swimming time (3), number of entries to the target quadrant (1), time spent in the opposite quadrant (1). | |
| Reversal trial: Escape latency (4). | |
| Visible platform trial test: escape latency (3), swimming speed (1). | |
| Novel object recognition task (6) | Percentage of new object exploration time/total exploration time (6), percentage of new object exploration numbers/total exploration numbers (2), percentage of old object exploration time/total exploration time (2), total exploration time (2). |
| Y maze (6) | Total reaction time (2), total entry frequencies in three arms (2), spontaneous alternations (2), duration in novel arm (1), frequency in novel arm (1), reaction time of getting learning skills (1) |
| Open field test (3) | Duration spent in the central zone (2), the frequency of crossing the central zone (1), distance in the central region (1), number of mice standing upright (1), activity distance (1). |
| Step-down avoidance test (2) | Latency period (2), number of errors (2). |
| Step-through test (1) | Mean number of errors of each group in the learning session (1), mean learning latency of each group in the learning session (1), mean number of errors of each group in the test session (1), mean test latency of each group in the test session (1). |
| Passive avoidance test (1) | Mean number of errors of each group in the learning session (1), mean learning latency of each group in the learning session (1), mean number of errors of each group in the test session (1), mean test latency of each group in the test session (1). |
| Escape/Avoidance training (1) | The number of escape responses (1), the response latency in escaping UCS shock (1). |
| Tightrope test (1) | Success rate (1). |
| Fear conditioning (1) | Percentage of animals frozen in the contextual test (1), percentage of animals frozen in cued test (1). |
Biochemical detection analyses.
| Tissue samples ( | Tests ( | Evaluation indicators ( | |
|---|---|---|---|
| Biochemical | Hippocampus (55), Cortex (8), serum (7), The frontal lobe cortex (6), prefrontal cortex (3), Cerebral cortex (2), Urine (2), Intestinal tissue (1), Dorsal raphe nucleus (1), Hypothalamus (1), Pituitary gland (1), Ovaries (1), Entorhinal cortex (1), cerebrospinal interstitial fluid (1), The parietal association cortex (1), stool (1), Cerebrospinal fluid (1), plasma (1) | Western blot (48), Immunohistochemistry (23), Immunofluorescence staining (19), RT-PCR (18), ELISA (14), Hematoxylin-eosin staining (10), Transmission electron microscopy (7), Nissl staining (6), TUNEL staining (4), Flow cytometry analysis (4), Immunoprecipitation (3), spectrophotometry (3), golgi staining (2), UPLC-MS (2), bisulfite sequencing (1), 16S rDNA amplicon sequencing (1), glucose oxidase method (1), GC-MS (1), Double-label immunofluorescence assays (1), BrdU staining (1), ROS staining (1), thioflavin staining (1), Colorimetric method (1), Optical fractionator method (1), Thiobarbituric acid method (1), Dithiodinitrobenzoic acid method (1), Xanthine oxidase method (1), Liquid chromatography-tandem mass spectrometry (1) | IL-1 |
| Other | — | Micro-PET (14), electrophysiology (3), Dynamic contrast enhancing (DCE)-MRI (1), arterial spin- labeling–functional MRI (ASL-fMRI) (1), MRI (1), MRS (1) | 18F-FDG (14), fEPSP slope (2), signal intensity of ROIs (2), CBF (1), NAA/CrF (1), glu/CrF (1), MI/CrF (1), time-dependent anatomical routes of paravascular influx in the glymphatic system (1), I/O curve (1), LTP (1), Potentiation (1), PS amplitude of baseline (1) |
Othera includes 125 indicators, each appearing only once.